BSEM (BioStem Technologies) Beneish M-Score: 41.85 (As of Jun. 26, 2026)

What is BioStem Technologies Beneish M-Score?

BioStem Technologies BSEM +3.20% 49 Beneish M-Score is 41.85 as of Jun. 26, 2026. GuruFocus rates BSEM with a GF Score™ of 49/100 and a GF Value™ of $139.96 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 831 Biotechnology companies, BioStem Technologies ranks worse than 97.71% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Warning Sign:

Beneish M-Score 41.85 higher than -1.78, which implies that the company might have manipulated its financial results.

The historical rank and industry rank for BioStem Technologies's Beneish M-Score or its related term are showing as below:

BSEM' s Beneish M-Score Range Over the Past 10 Years
Min: -14.88 Med: -0.06 Max: 358.12
Current: 41.85

During the past 13 years, the highest Beneish M-Score of BioStem Technologies was 358.12. The lowest was -14.88. And the median was -0.06.

BioStem Technologies Beneish M-Score Related Terms

BioStem Technologies Beneish M-Score Historical Data

* Premium members only.

The historical data trend for BioStem Technologies's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioStem Technologies Beneish M-Score Chart

BioStem Technologies Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Beneish M-Score

Get a 7-Day Free Trial

-4.95

-0.82

-11.78

14.71

64.63

BioStem Technologies Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Sep21	Dec21	Mar22	Sep22	Dec22	Mar23	Sep23	Dec23	Sep24	Dec24	Sep25
Beneish M-Score	Get a 7-Day Free Trial															-7.35	14.71	358.12	64.63	41.85

BSEM vs TCRX, BYSI, MCRB: Beneish M-Score Comparison

For the Biotechnology subindustry, BioStem Technologies's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioStem Technologies Beneish M-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioStem Technologies's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where BioStem Technologies's Beneish M-Score falls into.

Save Embed

49GF Score

BioStem Technologies Inc BSEM

Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

BioStem Technologies Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of BioStem Technologies for today is based on a combination of the following eight different indices:

-4.84

0.92 * DSRI

0.528 * GMI

0.404 * AQI

0.892 * SGI

0.115 * DEPI

-4.84

0.92 * 0.1406

0.528 * 0.898

0.404 * 0.7181

0.892 * 49.0836

0.115 * 2.8967

0.172 * SGAI

4.679 * TATA

0.327 * LVGI

0.172 * 0.5066

4.679 * 0.386983

0.327 * 0.1238

41.85

This Year (Sep25) TTM:

Last Year (Sep23) TTM:

Total Receivables was $20.1 Mil.
Revenue was 10.473 + 254.811 + 18.413 + 11.541 = $295.2 Mil.
Gross Profit was 9.269 + 251.276 + 14.174 + 10.913 = $285.6 Mil.
Total Current Assets was $52.7 Mil.
Total Assets was $62.4 Mil.
Property, Plant and Equipment(Net PPE) was $4.9 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.3 Mil.
Selling, General, & Admin. Expense(SGA) was $262.6 Mil.
Total Current Liabilities was $12.2 Mil.
Long-Term Debt & Capital Lease Obligation was $0.2 Mil.
Net Income was 0.761 + 15.52 + 6.82 + -0.51 = $22.6 Mil.
Non Operating Income was -0.123 + 0 + 0 + -0.008 = $-0.1 Mil.
Cash Flow from Operations was 0 + 0 + 0 + -1.423 = $-1.4 Mil.

Total Receivables was $2.9 Mil.
Revenue was 3.5 + 0.576 + 0.793 + 1.146 = $6.0 Mil.
Gross Profit was 3.175 + 0.475 + 0.668 + 0.908 = $5.2 Mil.
Total Current Assets was $3.8 Mil.
Total Assets was $5.8 Mil.
Property, Plant and Equipment(Net PPE) was $1.4 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.2 Mil.
Selling, General, & Admin. Expense(SGA) was $10.6 Mil.
Total Current Liabilities was $7.9 Mil.
Long-Term Debt & Capital Lease Obligation was $1.4 Mil.

1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI	=	(Receivables_t / Revenue_t)	/	(Receivables_t-1 / Revenue_t-1)
	=	(20.105 / 295.238)	/	(2.913 / 6.015)
	=	0.068098	/	0.484289
	=	0.1406

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI	=	GrossMargin_t-1	/	GrossMargin_t
	=	(GrossProfit_t-1 / Revenue_t-1)	/	(GrossProfit_t / Revenue_t)
	=	(5.226 / 6.015)	/	(285.632 / 295.238)
	=	0.868828	/	0.967464
	=	0.898

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI	=	(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t)	/	(1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
	=	(1 - (52.692 + 4.9) / 62.393)	/	(1 - (3.798 + 1.393) / 5.814)
	=	0.076948	/	0.107155
	=	0.7181

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI	=	Sales_t	/	Sales_t-1
	=	Revenue_t	/	Revenue_t-1
	=	295.238	/	6.015
	=	49.0836

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI	=	(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1))	/	(Depreciation_t / (Depreciaton_t + PPE_t))
	=	(0.234 / (0.234 + 1.393))	/	(0.256 / (0.256 + 4.9))
	=	0.143823	/	0.049651
	=	2.8967

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI	=	(SGA_t / Sales_t)	/	(SGA_t-1 /Sales_t-1)
	=	(262.551 / 295.238)	/	(10.559 / 6.015)
	=	0.889286	/	1.755445
	=	0.5066

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI	=	((LTD_t + CurrentLiabilities_t) / TotalAssets_t)	/	((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
	=	((0.158 + 12.218) / 62.393)	/	((1.41 + 7.907) / 5.814)
	=	0.198356	/	1.602511
	=	0.1238

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA	=	(IncomefromContinuingOperations_t	-	CashFlowsfromOperations_t)	/	TotalAssets_t
	=	(NetIncome_t - NonOperatingIncome_t	-	CashFlowsfromOperations_t)	/	TotalAssets_t
	=	(22.591 - -0.131	-	-1.423)	/	62.393
	=	0.386983

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

BioStem Technologies has a M-score of 41.85 signals that the company is likely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →

What does a Beneish M-Score of 41.85 mean?

BioStem Technologies (BSEM) has a Beneish M-Score of 41.85 as of Jun. 26, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on BioStem Technologies and its competitors. According to the industry distribution chart, BioStem Technologies ranks #812 out of 831 companies in the Biotechnology industry, placing it in the top 97.7%.

Is BioStem Technologies' Beneish M-Score too high?

BioStem Technologies' current Beneish M-Score is 41.85. Based on the distribution chart, BioStem Technologies ranks #812 out of 831 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, BioStem Technologies has a GF Score™ of 49/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.

How does BioStem Technologies' Beneish M-Score compare to TCRX and BYSI?

According to the Biotechnology industry distribution chart, BioStem Technologies ranks #812 out of 831 companies for Beneish M-Score. This places BioStem Technologies in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Beneish M-Score for a Biotechnology company?

A good Beneish M-Score depends on the Biotechnology industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Beneish M-Score mean?

A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on BioStem Technologies and its competitors. BioStem Technologies's current Beneish M-Score is 41.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is BioStem Technologies stock overvalued right now?

Based on GuruFocus' analysis, BioStem Technologies (BSEM) is currently considered Possible Value Trap. The stock's GF Value™ is $139.96, compared to a current price of $3.55 — trading 97.5% below its estimated fair value. The current Beneish M-Score is 41.85. BioStem Technologies' overall GF Score™ is 49/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Beneish M-Score calculated?

Beneish M-Score is calculated from a company's financial statements. For BioStem Technologies (BSEM), the current Beneish M-Score is 41.85 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BioStem Technologies (BSEM) Overvalued in 2026?

Based on GuruFocus' analysis, BioStem Technologies stock appears to be undervalued. The current stock price of $3.55 is trading 97.5% below its estimated GF Value™ of $139.96. GuruFocus considers BioStem Technologies to be Possible Value Trap.

Key valuation signals for BSEM:

Beneish M-Score: 41.85
GF Value™: $139.96 vs. price of $3.55 (97.5% below fair value)
GF Score™: 49/100 with 3 warning signs

No single metric tells the full story. See the BSEM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BioStem Technologies Business Description

Industry Healthcare Biotechnology

Comparable Companies TCRX BYSI MCRB ACRV MNOV XBIT ENTX IMA FLNA EDSA VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270

Address 2836 Center Port Circle, Pompano Beach, FL, USA, 33064

Website https://www.biostemtechnologies.com

BioStem Technologies Inc is a regenerative biotechnology company focused on harnessing elements of perinatal tissue and the body's innate biology to repair or reverse damage caused by a broad range of degenerative diseases. The company develops, manufactures, and sells tissue allografts for the wound care market with a focus on the treatment of diabetic, pressure, and venous ulcers. Utilizing its proprietary BioRetain processing method, it manufactures perinatal tissue allografts. The company offers a comprehensive portfolio of high-quality brands that are trademarked and include VENDAJE AC, AmnioWrap2, and Others. The company generates key revenue from VENDAJE AC.

49GF Score

Get the complete analysis for BSEM

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.55

Price

$139.96

GF Value

View BSEM Analysis

See Beneish M-Score data for all stocks →